A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers
about
Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsSafety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumoursMitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.Parthenogenetic activation and somatic cell nuclear transfer of porcine oocytes activated by an electric pulse and AZD5438 treatment.
P2860
A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers
description
im November 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 18 November 2006
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2006
@uk
name
A first-in-man phase I tolerab ...... 438 in healthy male volunteers
@en
A first-in-man phase I tolerab ...... 438 in healthy male volunteers
@nl
type
label
A first-in-man phase I tolerab ...... 438 in healthy male volunteers
@en
A first-in-man phase I tolerab ...... 438 in healthy male volunteers
@nl
prefLabel
A first-in-man phase I tolerab ...... 438 in healthy male volunteers
@en
A first-in-man phase I tolerab ...... 438 in healthy male volunteers
@nl
P2093
P1476
A first-in-man phase I tolerab ...... 438 in healthy male volunteers
@en
P2093
D Ross Camidge
Dominic Smethurst
Helen Swaisland
Jim Growcott
John R Foster
Nigel C Barrass
Salvatore Febbraro
P2888
P304
P356
10.1007/S00280-006-0371-X
P577
2006-11-18T00:00:00Z